(...) In the present project we want to address two main guidelines: 1- to further study the molecular pathways that lead to survival \i in vivo\i0 and in cerebellar granule neurons (CGN), analyzing the effecto of Hc on some transcription factors and on other pathways different from the studied until now, as well as the interaction with the neurotrophin receptor p75\super NTR\nosuper, and 2- to continue the studies of neuronal protection \i in vivo\i0, with the aim to explore the possible therapeutical application of Hc in diseases wich neuronal death is a key component. In the \i in vivo\i0 investigation, the unilateral lesion of the brain will be used in rats, by means of sterotaxically injection of MPP\super +\nosuper o 6-hidroxidopamine. A mouse strain sensible to peripherally injected MPTP (a MPP\super +\nosuper precursor) will be also used. Each of the injected compounds induces experimental Parkinson's disease (PD) , which will be hypothetically attenuated by the peripheral administration of Hc. The determination of the anti-PD effect will be assessed in basis of the chatecholamines levels, the TH and dopamine transporter effectors and the motor capabilities, by means of the measurement of the metanphetamine-induced rotation behaviour, as well as the determination of the motor coordination using the Rota-rod apparatus.
|Effective start/end date||1/10/06 → 30/09/09|